8-K: Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million

Ligand Pharmaceuticals announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash and stock, significantly expanding its royalty portfolio.

Summary

• Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million.
• The acquisition involves a cash payment of $39.00 per share for XOMA Royalty common stock.
• XOMA Royalty stockholders will also receive a non-transferable Contingent Value Right (CVR) per share, representing a portion of 75% of net proceeds from certain pending litigation.
• The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including XOMA Royalty stockholder approval and regulatory approvals.
• Ligand anticipates the acquisition will be immediately accretive to its adjusted EPS, with an expected $1.50 per share accretion in 2027.
• The deal significantly expands Ligand's royalty portfolio to over 200 assets, adding seven new commercial products and nearly doubling its portfolio of Phase 2 and 3 assets.
• Ligand is increasing its 2026 revenue guidance to $270 million - $310 million and its adjusted EPS guidance to $8.50 - $9.50.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive development, driven by the strategic fit, immediate accretion, and significant expansion of Ligand's royalty portfolio.

Positives

• Acquisition is expected to be immediately accretive to Ligand's adjusted EPS, with an estimated $0.50 accretion in 2026 and $1.50 in 2027.
• Significantly expands Ligand's royalty portfolio to over 200 assets, adding seven new commercial products and nearly doubling Phase 2 and 3 assets.
• Diversifies Ligand's portfolio across development stages, therapeutic areas, and modalities.
• Adds complementary assets and strengthens Ligand's position as a leading biopharma royalty aggregator.
• Ligand increases its 2026 revenue guidance to $270 million - $310 million (previously $245 million - $285 million).
• Ligand raises its 2026 adjusted EPS guidance to $8.50 - $9.50 (previously $8.00 - $9.00).
• Expected to generate significant financial synergies through the elimination of duplicative public company costs.
• The transaction is funded through Ligand's existing cash on hand and existing credit facility, avoiding the need for new financing.

Negatives

• The acquisition is subject to customary closing conditions, including XOMA Royalty stockholder approval and regulatory approvals, which may not be obtained.
• There is a risk that the anticipated benefits of the acquisition may not be realized or may not be realized within the expected timeframe.
• The integration of the two businesses may disrupt operations and make it more difficult to maintain business and operational relationships.
• Significant transaction costs are associated with the acquisition.
• Unknown liabilities could arise from the transaction.
• The CVR is contingent on the outcome of ongoing litigation with Janssen Biotech, which is uncertain.
• XOMA Royalty may be required to pay a termination fee of $40,000,000 under specific circumstances.

Risks

• Risks related to the satisfaction or waiver of closing conditions, including failure to obtain necessary regulatory approvals and XOMA Royalty stockholder approval.
• Possibility of competing offers for XOMA Royalty.
• Risks associated with integrating the businesses and maintaining business and operational relationships.
• Potential for litigation and regulatory actions related to the acquisition or XOMA Royalty's business.
• Uncertainties regarding the commercial success of existing and pipeline products from both companies.
• Reliance on collaborative partners for milestone payments, royalties, and other revenue projections, which may not be received.
• Risks associated with drug development, including clinical trial outcomes, regulatory approvals, and market acceptance.
• The outcome of the ongoing litigation with Janssen Biotech regarding TREMFYA is uncertain and impacts the value of the CVR.

Future Outlook

Ligand Pharmaceuticals expects the acquisition of XOMA Royalty to be immediately accretive to its adjusted EPS, with an estimated $0.50 accretion in 2026 and $1.50 in 2027. The company has raised its 2026 revenue guidance to $270 million - $310 million and its adjusted EPS guidance to $8.50 - $9.50. The combined entity is projected to have a stronger long-term growth profile due to the expanded royalty portfolio.

Management Comments

• "The XOMA Royalty team has built a robust portfolio of complementary biopharmaceutical assets, and this acquisition will enable us to further grow and diversify in areas such as ophthalmology, oncology, CNS and rare diseases."
• "With XOMA Royalty, we believe we will now be in an even stronger position to leverage our expertise and capital base to support broader patient access and advance late-stage clinical programs in a way that enhances patient outcomes and improves lives."
• "After evaluating a broad range of strategic and financing alternatives, we believe combining our diverse portfolio with a company that shares our commitment to helping the biopharmaceutical industry thrive represents the most compelling outcome for XOMA Royalty's stockholders."
• "The structure delivers to our stockholders both the intrinsic value of XOMAs portfolio today and the optionality associated with our ongoing litigation with Janssen Biotech (now Johnson & Johnson Innovative Medicine) via the CVR."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the trend of larger biopharmaceutical companies consolidating royalty portfolios to enhance diversification and accelerate growth, particularly in the royalty aggregator space. The move by Ligand to acquire XOMA Royalty strengthens its position and expands its reach into new therapeutic areas and development stages.

Comparison to Industry Standards

• The acquisition price of $39.00 per share represents a 14% premium to XOMA Royalty's 30-day volume-weighted average price, which is within typical ranges for such transactions.
• Ligand's increased 2026 adjusted EPS guidance of $8.50-$9.50 reflects the expected accretive nature of the deal, a key metric for evaluating such acquisitions.
• The addition of over 120 partnered programs, including seven commercial assets and 14 late-stage development programs, significantly bolsters Ligand's portfolio against industry benchmarks for royalty aggregators.
• The inclusion of assets like Roche's VABYSMO and Day One Pharmaceuticals' OJEMDA, which are significant commercial products, positions the combined entity competitively within the biopharma royalty landscape.

Legal Proceedings

• XOMA Royalty is involved in ongoing litigation with Janssen Biotech (now Johnson & Johnson Innovative Medicine) regarding the commercialization of TREMFYA, the outcome of which will determine the proceeds from the CVR.

Related Party Transactions

• Entities affiliated with BVF Partners, which own approximately 47% of XOMA Royalty's shares (including Series X Preferred Shares on an as-converted basis), have entered into Support Agreements to vote in favor of the transaction.

Stakeholder Impact

• Shareholders of XOMA Royalty will receive $39.00 per share in cash plus a CVR, providing immediate value and potential upside from litigation.
• Ligand shareholders benefit from an expanded and diversified royalty portfolio, increased revenue and EPS guidance, and expected long-term growth.
• Employees of both companies may face integration challenges and potential redundancies, though specific impacts are not detailed.
• Collaborative partners of both companies will interact with a larger, more diversified entity, potentially leading to new opportunities or changes in existing relationships.

Next Steps

• Obtain XOMA Royalty stockholder approval for the merger agreement.
• Secure necessary regulatory approvals.
• Complete the Holding Company Reorganization and CVR Spin prior to the merger.
• Close the transaction, expected in the third quarter of 2026.

Key Dates

Recommendation

The acquisition is strategically sound, immediately accretive, and significantly enhances Ligand's market position and future growth prospects. The increased financial guidance and expanded portfolio offer compelling value for investors.

Keywords

Ligand Pharmaceuticals, XOMA Royalty, Merger, Acquisition, Royalty Aggregator, Biotechnology, Contingent Value Right, SEC Filing